Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15572916 | 0.98 | ALDH1A1 (0.32) | CPB2 | |
| SCHEMBL11599065 | 0.78 | — | — | |
| SCHEMBL5797547 | 0.77 | CPN1 (0.31) | CPB2 | |
| SCHEMBL4681723 | 0.77 | AKT1 (0.35) | — | |
| SCHEMBL5598602 | 0.76 | — | — | |
| SCHEMBL196537 | 0.76 | — | — | |
| SCHEMBL516848 | 0.76 | — | — | |
| SCHEMBL516849 | 0.76 | — | — | |
| SCHEMBL1005721 | 0.76 | — | — | |
| SCHEMBL11119178 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907288-A | Application of nitrobenzene compounds in preparation of pseudomonas aeruginosa quorum sensing inhibitor | 中国医学科学院医药生物技术研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-7067532-B2 | Substituted quinolines as antitumor agents | ASTRAZENECA (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | disclosed |
| EP-1337524-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002044166-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-0730591-B1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | UPJOHN CO (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5763631-A | CIS-EPOXIDE COMPOUNDS; ANTIVIRUS AGENTS; USEFUL TO TREAT THE AIDS | LUCKY LIMITED (KR) | 1998-06-09 | — | — | US | disclosed |
| US-5744621-A | CIS-EPOXIDE COMPOUNDS | LUCKY LIMITED. (KR) | 1998-04-28 | — | — | US | disclosed |
| US-5652238-A | WATER SOLUBILITY; ANTIMICROBIAL AGENTS EFFECTIVE AGAINST RESISTANT STAPHYLOCOCCI, ENTEROCOCCI, AND STREPTOCOCCI | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5587388-A | AIDS; VIRICIDES | LUCKY LIMITED (KR) | 1996-12-24 | — | — | US | disclosed |
| EP-0730591-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014684-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | THE UPJOHN COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | CPB2 4734/4885TSHR 161/4885 |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | NQO2, NQO1, TP53 | CPB2 4102/4885TSHR 4338/4885 |
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | CPB2 3458/4885TSHR 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.